Center for Molecular Medicine Cologne

Cabreiro, Filipe | Corrado, Mauro | Solagna, Francesca - B 02

Role of gut microbiota on the onset of sarcopenia

Introduction

Frailty is a major challenge for elders and its most obvious sign is the involuntary loss of skeletal muscle mass and function (sarcopenia). It is related to a series of economic and social implications, including hospitalization, morbidity, and mortality. A major challenge in finding a treatment for sarcopenia is its multifactorial origin. It involves several pathophysiological mechanisms and the cross-talk between different organs. The promising research endeavours in this area are the identification of early biomarkers and actionable mechanisms. Age-related dysbiosis has been recently proposed as a hallmark of ageing. We hypothesize that dysbiosis plays a key role in the development of sarcopenia. This may represent a key biomarker regulating the transition between healthy, pre-frail and frail. Using a multi-omic approach we will now dissect the role of gut microbiota in the development of sarcopenia and identify tissue cross-talk regulators modulated by the microbiota.

Clinical Relevance

The ability to manipulate the microbiota holds great potential towards improving human health. By identifying bacterial species and their metabolites that regulate key signaling/cellular processes in sarcopenia during ageing, this proposal will create new therapeutic opportunities. Further, it can lead to the identification of early predictive molecular biomarkers of sarcopenia that may inform medical decisions based on the future profiling of a patient’s genetics and microbiome function.

Approach

  1. Why do changes in the composition of the gut microbiota occur with age? Is there a causal relationship with the onset of sarcopenia?
  2. Is age-related microbiota dysbiosis promoting the development of sarcopenia? Or is dysbiosis the consequence of sarcopenia-related muscle catabolism?
  3. Which is the role of gut-derived metabolites in inter-organ communication during aging?

Bana, B. et al., Annu Rev Genet, 2019. 53: p. 239-261. DOI: 10.1146/annurev-genet-112618-043650
Pryor, R., et al., Cell. 2019 Sep 5; 178(6): 1299–1312.e29.
Scott, T.A., et al.,
Cell. 2017 Apr 20; 169(3): 442–456.e18.
Solagna, F., et al.,
Acta Physiol (Oxf). 2020 Sep; 230(1): e13496.
Solagna, F., et al.,
J Clin Invest. 2021 Jun 1; 131(11): e135821.
Corrado, M., et al.,
Cell Metab. 2020 Dec 1; 32(6): 981–995.e7.
Corrado, M. et al.,
J Clin Invest. 2022 Jan 4; 132(1): e148546.

Prof. Dr. Filipe Cabreiro CMMC Cologne
Prof. Dr. Filipe Cabreiro

CECAD Excellent in Aging Research

CMMC - PI - B 02

+49 221 478 84390

CECAD Excellent in Aging Research

Joseph-Stelzmann-Straße 26

50931 Cologne

http://www.cabreirolab.org/

CMMC Profile Page

Curriculum Vitae (CV)

Publications on PubMed

Publications - Filipe Cabreiro

Link to PubMed

Dr. Mauro Corrado CMMC Cologne
Dr. Mauro Corrado

CECAD Research Center

CMMC - PI - B 03
CMMC - PI - CAP 21
CMMC - Co-PI - B 02

+49 221 478 84167

CECAD Research Center

Joseph-Stelzmann-Str. 26

50931 Cologne

CMMC Profile Page

Curriculum Vitae (CV)

Publications - Mauro Corrado

Link to PubMed

Dr. Franceca Solagna CMMC Cologne
Dr. Franceca Solagna

CECAD Research Building

CMMC - Co-PI - B 02

CECAD Research Building

Joseph-Stelzmann-Straße 26

50931 Cologne

https://www.cecad.uni-koeln.de/home

CMMC Profile Page

Curriculum Vitae (CV)

Publications on PubMed

Publication - Francesca Solagna

Link to PubMed

Affiliations - Francesca Solagna

CECAD
Institute for Genetics

Group Members

Lab Manager
Chrysa Nikopoulou
PostDoc
Francesca Solagna, Daniel Martinez-Martinez,
Tanara Peres

PhD student
Jennifer Van der Laan, Marie Blickling,
Andreea Aprodu, Kristin Gehling

Master student
Hyejin Hwang
Technician
Ayesha Safoor